Spyre Therapeutics, Inc. (SYRE)

Market Cap	4.97B +384.4%
Revenue (ttm)	n/a
Net Income	-126.54M
EPS	-1.98
Shares Out	78.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,360,876
Open	67.00
Previous Close	51.29
Day's Range	59.02 - 75.00
52-Week Range	12.04 - 75.00
Beta	2.94
Analysts	Strong Buy
Price Target	72.78 (+15.03%)
Earnings Date	May 7, 2026

About SYRE

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the α4β7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also develo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 7, 2016
• Employees: 102
• Stock Exchange: NASDAQ
• Ticker Symbol: SYRE
• Website: https://www.spyre.com

Analyst Summary

According to 9 analysts, the average rating for SYRE stock is "Strong Buy." The 12-month stock price target is $72.78, which is an increase of 15.03% from the latest price.

Price Target

$72.78

(15.03% upside)

Analyst Consensus: Strong Buy